PE20071149A1 - Derivados de benzimidazol - Google Patents
Derivados de benzimidazolInfo
- Publication number
- PE20071149A1 PE20071149A1 PE2007000352A PE2007000352A PE20071149A1 PE 20071149 A1 PE20071149 A1 PE 20071149A1 PE 2007000352 A PE2007000352 A PE 2007000352A PE 2007000352 A PE2007000352 A PE 2007000352A PE 20071149 A1 PE20071149 A1 PE 20071149A1
- Authority
- PE
- Peru
- Prior art keywords
- metoxy
- pyridin
- halogen
- phenyl
- alkyl
- Prior art date
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- -1 AMINOCARBONYL Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 102000003982 Parathyroid hormone Human genes 0.000 abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 2
- 239000000199 parathyroid hormone Substances 0.000 abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 abstract 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE BENZIMIDAZOL DE FORMULA (I) DONDE R ES HALOGENO O ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALOGENO, OH, SULFONILO, NH2, ENTRE OTROS; X ES O, NH, CH2, CO, SO, ENTRE OTROS; Y ES ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALOGENO, OH, ALQUILO(C1-C6), AMINOCARBONILO, ENTRE OTROS SUSTITUYENTES, SR1, S(O)R1, OR2, ENTRE OTROS, DONDE R1 Y R2 SON CADA UNO ALQUILO(C1-C6), ALQUENILO(C2-C4) O ALQUINILO(C2-C4). SON COMPUESTOS PREFERIDOS: 2-(4-ISOPROPIL-FENIL-7-METOXI-1-(2-METOXI-ETIL)-5-(2-METILSULFANIL-PIRIDIN-3-ILMETIL)-4-TRIFLUOROMETIL-1H-BENZOIMIDAZOL, 4-BROMO-2-(4-ISOPROPIL-FENIL)-5-(2-METANSULFINIL-PIRIDIN-3-ILMETIL)-7-METOXI-1-(2-METOXI-ETIL)-1H-BENZOIMIDAZOL, 2-(4-ISOPROPIL-FENIL)-5-(2-METANSULFINIL-PIRIDIN-3-ILMETIL)-7-METOXI-1-(2-METOXI-ETIL)-4-TRIFLUOROMETIL-1H-BENZOIMIDAZOL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS PROMUEVEN LA LIBERACION DE LA HORMONA PARATIROIDES (PTH) SIENDO UTILES EN EL TRATAMIENTO DE OSTEOPOROSIS, OSTEOPATIA, OSTEOMALACIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0606426.5A GB0606426D0 (en) | 2006-03-30 | 2006-03-30 | Benzimidazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20071149A1 true PE20071149A1 (es) | 2007-12-04 |
Family
ID=36424926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000352A PE20071149A1 (es) | 2006-03-30 | 2007-03-28 | Derivados de benzimidazol |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20100227889A1 (es) |
| EP (1) | EP2004629A2 (es) |
| JP (1) | JP2009531363A (es) |
| KR (1) | KR20080110769A (es) |
| CN (1) | CN101400669A (es) |
| AR (1) | AR060334A1 (es) |
| AU (1) | AU2007234021B2 (es) |
| BR (1) | BRPI0710180A2 (es) |
| CA (1) | CA2644380A1 (es) |
| CL (1) | CL2007000850A1 (es) |
| CR (1) | CR10199A (es) |
| EC (1) | ECSP088781A (es) |
| GB (1) | GB0606426D0 (es) |
| GT (1) | GT200800200A (es) |
| IL (1) | IL193475A0 (es) |
| MA (1) | MA30341B1 (es) |
| MX (1) | MX2008012403A (es) |
| NO (1) | NO20084543L (es) |
| PE (1) | PE20071149A1 (es) |
| RU (1) | RU2008142831A (es) |
| TN (1) | TNSN08369A1 (es) |
| TW (1) | TW200806647A (es) |
| WO (1) | WO2007112913A2 (es) |
| ZA (1) | ZA200806833B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1993559T1 (sl) | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3 |
| DK3357496T3 (da) | 2006-06-21 | 2020-05-11 | Opko Ireland Global Holdings Ltd | Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel |
| PT2148661E (pt) | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
| PT2148684E (pt) | 2007-04-25 | 2013-04-19 | Cytochroma Inc | Método de tratamento para a insuficiência e deficiência de vitamina d |
| US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| CN103228629A (zh) * | 2010-11-26 | 2013-07-31 | 利奥制药有限公司 | 作为CaSR活性化合物的被取代的环戊基-氮杂苯类 |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| WO2017182237A1 (en) | 2016-03-28 | 2017-10-26 | Opko Ireland Global Holdings, Limited | Methods of vitamin d treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000026430A (ja) * | 1998-07-02 | 2000-01-25 | Taisho Pharmaceut Co Ltd | ２、５、６−置換ベンズイミダゾール化合物誘導体 |
| US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| JP2006513159A (ja) * | 2002-11-01 | 2006-04-20 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体 |
| GB0400781D0 (en) * | 2004-01-14 | 2004-02-18 | Novartis Ag | Organic compounds |
| EP1964548A1 (en) * | 2007-03-02 | 2008-09-03 | Novartis AG | Pharmaceutical compositions comprising a calcilytic agent |
-
2006
- 2006-03-30 GB GBGB0606426.5A patent/GB0606426D0/en not_active Ceased
-
2007
- 2007-03-28 AR ARP070101297A patent/AR060334A1/es not_active Application Discontinuation
- 2007-03-28 JP JP2009501943A patent/JP2009531363A/ja not_active Withdrawn
- 2007-03-28 AU AU2007234021A patent/AU2007234021B2/en not_active Ceased
- 2007-03-28 EP EP07723708A patent/EP2004629A2/en not_active Withdrawn
- 2007-03-28 CA CA002644380A patent/CA2644380A1/en not_active Abandoned
- 2007-03-28 WO PCT/EP2007/002763 patent/WO2007112913A2/en not_active Ceased
- 2007-03-28 MX MX2008012403A patent/MX2008012403A/es not_active Application Discontinuation
- 2007-03-28 RU RU2008142831/04A patent/RU2008142831A/ru not_active Application Discontinuation
- 2007-03-28 BR BRPI0710180-5A patent/BRPI0710180A2/pt not_active IP Right Cessation
- 2007-03-28 US US12/295,381 patent/US20100227889A1/en not_active Abandoned
- 2007-03-28 CN CNA2007800087520A patent/CN101400669A/zh active Pending
- 2007-03-28 KR KR1020087023787A patent/KR20080110769A/ko not_active Withdrawn
- 2007-03-28 PE PE2007000352A patent/PE20071149A1/es not_active Application Discontinuation
- 2007-03-29 CL CL200700850A patent/CL2007000850A1/es unknown
- 2007-03-29 TW TW096111055A patent/TW200806647A/zh unknown
-
2008
- 2008-08-07 ZA ZA200806833A patent/ZA200806833B/xx unknown
- 2008-08-11 CR CR10199A patent/CR10199A/es not_active Application Discontinuation
- 2008-08-14 IL IL193475A patent/IL193475A0/en unknown
- 2008-09-22 TN TNP2008000369A patent/TNSN08369A1/en unknown
- 2008-09-29 GT GT200800200A patent/GT200800200A/es unknown
- 2008-09-30 EC EC2008008781A patent/ECSP088781A/es unknown
- 2008-10-17 MA MA31302A patent/MA30341B1/fr unknown
- 2008-10-28 NO NO20084543A patent/NO20084543L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007112913A2 (en) | 2007-10-11 |
| NO20084543L (no) | 2008-10-21 |
| TNSN08369A1 (en) | 2009-12-29 |
| GT200800200A (es) | 2008-11-10 |
| TW200806647A (en) | 2008-02-01 |
| CN101400669A (zh) | 2009-04-01 |
| AU2007234021B2 (en) | 2011-04-28 |
| GB0606426D0 (en) | 2006-05-10 |
| CL2007000850A1 (es) | 2008-03-14 |
| BRPI0710180A2 (pt) | 2011-08-09 |
| AU2007234021A1 (en) | 2007-10-11 |
| ECSP088781A (es) | 2008-10-31 |
| WO2007112913A3 (en) | 2007-12-21 |
| ZA200806833B (en) | 2009-05-27 |
| CR10199A (es) | 2008-10-16 |
| MA30341B1 (fr) | 2009-04-01 |
| KR20080110769A (ko) | 2008-12-19 |
| US20100227889A1 (en) | 2010-09-09 |
| RU2008142831A (ru) | 2010-05-10 |
| IL193475A0 (en) | 2009-05-04 |
| EP2004629A2 (en) | 2008-12-24 |
| CA2644380A1 (en) | 2007-10-11 |
| JP2009531363A (ja) | 2009-09-03 |
| MX2008012403A (es) | 2008-10-07 |
| AR060334A1 (es) | 2008-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20071149A1 (es) | Derivados de benzimidazol | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PE20121282A1 (es) | Antagonistas de espiro-oxindol de mdm2 | |
| PE20120691A1 (es) | Derivados de n1-sulfonil-5-fluoropirimidinona | |
| PE20140608A1 (es) | Analogos de nucleotidos sustituidos | |
| PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20080927A1 (es) | Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk) | |
| PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| PE20071223A1 (es) | Procedimiento de preparacion de derivados de acil-amino-alquilen-amida | |
| PE20060401A1 (es) | Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno | |
| PE20091370A1 (es) | Arilpirrolinas insecticidas | |
| CL2011001224A1 (es) | Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c. | |
| BRPI0910182A2 (pt) | composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto" | |
| PE20080697A1 (es) | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion | |
| PE20090992A1 (es) | Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa | |
| PE20060736A1 (es) | DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2 | |
| CL2010000667A1 (es) | Compuestos derivados de ciclohexil-piperazinil-metanona, antagonistas y/o agonistas inverso h3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de la obesidad, diabetes tipo ii y dislipidemia (sol. div. 60-07). | |
| PE20080150A1 (es) | Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch) | |
| PE20140934A1 (es) | Derivados de pirazol | |
| PE20091527A1 (es) | Derivados de piridazinona | |
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| PE20061377A1 (es) | Compuestos heterociclicos fusionados | |
| PE20120593A1 (es) | Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |